TROPION-Lung01 Study Design and Baseline demographics

Patient Disposition Screened (n=1003) Randomised (n=732) Daiichi-Sankyo Dato-DXd (n=365)* • Ongoing study treatment (n=93) Discontinued study treatment (n=267) - Progressive disease (n=229) Adverse event (n=11) ICC (n=367)* Ongoing study treatment (n=39) Discontinued study treatment (n=312) - Progressive disease (n=240) ICC: • Eribulin mesylate: n=220 Vinorelbine: n=38 • Capecitabine: n=76 1 Patient decision (n=13) —- Death (n=2) - Other (n=12) - Adverse event (n=10) 1 Patient decision (n=32) - Death (n=7) - Other (n=23) Median study follow-up: 10.8 months *360 and 351 patients received treatment with Dato-DXd and ICC, respectively. • Gemcitabine: n=33 Data cut-off. 17 July 2023. 28

View entire presentation